Group 1 - The core viewpoint of the article highlights that Valiant Pharmaceuticals-B (09887) experienced a significant stock price increase, rising over 6% in the afternoon trading session, with a current price of 68.65 HKD and a trading volume of 25.8866 million HKD [1] - The Hang Seng Index Company announced the results of its quarterly review, which included Valiant Pharmaceuticals in the Hang Seng Composite Index, with all changes to be implemented after market close on March 6 and effective from March 9 [1] - CICC released a research report indicating that Valiant Pharmaceuticals may be included in the Hong Kong Stock Connect in March [1] Group 2 - Western Securities noted that considering the company has multiple clinical data catalysts expected in 2026, it is anticipated to reach a commercialization inflection point in 2027 [1]
港股异动 | 维立志博-B(09887)午后涨超6% 下月有望成为港股通标的 公司即将进入商业化拐点